Kofituss Sedativo Tosse

Levodropropizine, the active ingredient in Kofituss Sedativo Tosse, is an antitussive presented as an oral formulation for oral use. It provides symptomatic relief of dry, non‑productive coughs in both adults and children, helping to reduce the frequency and intensity of the cough reflex. By acting on peripheral cough receptors, it offers an alternative to centrally acting opioid antitussives and minimizes the likelihood of central nervous system sedation.

GNH USA supplies Kofituss Sedativo Tosse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodropropizine is used as an oral antitussive to suppress coughs arising from irritation of the respiratory tract. - Dry cough: provides symptomatic relief by reducing the cough reflex without affecting mucus clearance. - Acute upper respiratory tract infection: helps lessen irritating cough associated with viral or bacterial infections. - Non‑productive bronchitis: alleviates persistent cough in bronchial inflammation when sputum production is minimal.

Levodropropizine is generally well tolerated, but some patients may experience adverse reactions ranging from mild to serious.

Common Side Effects: - Nausea: mild stomach upset occurring shortly after ingestion. - Headache: transient mild to moderate head pain. - Dry mouth: reduced salivation leading to a dry feeling in the mouth. - Dizziness: occasional light‑headed sensation, usually resolves without intervention.

Serious or Rare Side Effects: - Allergic reactions (rash, urticaria): skin eruptions that may require medical attention. - Angioedema or facial swelling: rapid swelling of lips, tongue or face, potentially airway‑compromising. - Hepatic dysfunction or severe neutropenia: abnormal liver enzymes or low white‑blood‑cell count, requiring laboratory monitoring.

Levodropropizine should be used with caution in specific populations and conditions. - Pregnancy: safety not established; use only if the potential benefit justifies the potential risk. - Breastfeeding: unknown excretion; consider possible effects on the infant before use. - Renal impairment: dose adjustment may be required; monitor renal function in patients with severe impairment. - Concomitant CNS depressants: may increase sedation; observe patients for enhanced drowsiness. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Potential drug interactions with levodropropizine should be reviewed before therapy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of additive central effects such as excessive sedation. - Strong CYP3A4 inhibitors: may increase levodropropizine plasma concentrations. - Other antitussives: combined use can lead to excessive cough suppression.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance sedative properties. - Antihistamines: can increase drowsiness. - Selective serotonin reuptake inhibitors: monitor for rare serotonin‑related effects.